CD79A and B-cell chronic lymphocytic leukemia: Moreover, the statistical analysis of serological profiles between EBV+ CLL and EBV+ CVID patients showed a statistically significant increase in anti-EBA EA IgA (1.41-fold); anti-EBV EA IgG (1.28-fold); anti-EBV VCA IgA (1.38-fold); anti-EBV VCA IgG (1.29-fold); and anti-EBV EBNA-1 IgA (1.20-fold) in CLL patients compared with CVID (Figure 3A,C,D,F,G).